Statement of the Problem: Phenytoin (PHT) has been known to promote wound healing in some medical conditions owing to its proliferative as well as antiinflammatory effects. Yet, its application in oral lesions was less investigated.
Introduction
Periodontitis is a common, multi-factorial disease, primarily caused by microbial plaque. [1] In the presence of periodontal disease, bleeding on probing indicates bacterial plaque, which in turn, causes inflammation and ulceration in the epithelial lining wall of the pocket. [2] Based on epidemiological findings, chronic periodontitis is the most prevalent form of periodontal disease which, if left untreated, will cause irreversible bone loss. [3] Periodontal pockets are chronic inflammatory lesions, which constantly undergo repair and destruction.
Thorough healing cannot be completed due to the remained bacterial plaque and persistent inflammatory response as well as subsequent degeneration. [4] The final outcome is brought about as a result of the interplay between destruction and construction. What tips the balance in favor of the latter includes infection eradication, inflammation relief and wound healing. [2] A relatively new agent for accelerating wound healing, phenytoin (PHT) has already been used as an anticonvulsant drug since 1938. [5] [6] A common sideeffect, gingival hyperplasia, reported in as many as 50% of patients on long-term phenytoin therapy. [6] [7] [8] [9] [10] [11] Deeply inspired, Shapiro initially assessed the potential effects of oral phenytoin on periodontal wound healing in 1958 with favorable outcomes. [5] [6] [7] [12] [13] [14] [15] This also motivated other research investigating potential effects in burns, trauma, leprosy, [15] [16] [17] aphthous stomatitis, [7, 11, 18] diabetes, and lichen planus. [7, 11] PHT supposedly contributes to healing via modulating cellular immunity as well as hindering white blood cells (WBC) migration. [11, 19] It may also indirectly stimulate proliferation and migration of fibroblasts through the expression of growth factor genes, namely platelet-derived growth factor (PDGF) from macrophages and monocytes. [16] The drug is also claimed to trigger collagen fibers' maturation, promote collagen deposition and enhance angiogenesis. [6, 9, [20] [21] Other desired effects regard edema reduction [22] by decreasing both exudate and transudate. [8, 16, 20] The antibacterial feature is still subject to controversy, yet the drug's potential effect in curtailing infection seems to be owing to enhanced blood flow as a result of the stimulus the pharmaceutical agent creates for angiogenesis. [7, 9] It is also claimed that PHT stabilizes neural fiber membranes, thus contributes in topical pain relief. [23] There has also been research on the role of phenytoin in improving periodontal parameters [13, 16, 22] as well as healing process in the extraction socket. [19] The previous investigators almost all applied topical phenytoin but in different forms: mouthwash, [7] suspension, [24] gel [12] and mucoadhesive paste. [14, 23] In this study, we primarily intended to investigate the effect of topical phenytoin use on periodontal indices.
Materials and Method
This was a double-blind, randomized, split-mouth controlled clinical study, conducted on 40 dental sites of twenty patients, five men and fifteen women, with a mean age of (36.2±12.2) years, diagnosed with moderate to severe chronic periodontitis. [25] Patients were included if they were nonsmokers, without any history of traumatic occlusion and systemic conditions namely diabetes and heart diseases. As for their drug history, they should not take antihypertensive, immune suppressants and anticonvulsants, which would have affected their periodontium. None were pregnant, nor had they taken antibiotics during last three months. They all had at least two contra-lateral teeth with similar conditions (number of roots, without furcation involvement and similar pocket depth) on posterior sextants, with no decay and restorations. All patients signed the informed consent form when an internist was consulted for medical assessment and possible drug interactions. Demographic data was provided via having patients filled a questionnaire whereas the rest was collected throughout oral examinations. Periodontal pocket depth (PPD), the distance from the gingival margin to the base of the probable crevice, was measured along six areas for each tooth (mesiobuccal, midbuccal, distobuccal, distolingual, midlingual and mesiolingual) using a William's periodontal probe. Bleeding on probing (BOP), sites which bled 30 to 60 seconds after probing in percentage terms, [26] as well as modified gingival index (MGI) were also recorded. [27] There were two periodontists both blind to the study. One clinician was assigned to carry out clinical measurements as described, both prior to applying the mucoadhesive paste, which was randomly (using toss of coin) chosen to be either PHT or placebo. This clinician also confirmed sufficient and acceptable oral hygiene before the measurements were calculated. All patients underwent thorough scaling, root-planning, and oral hygiene instructions such as bass brushing technique and flossing, conducted by a trained periodontology resident who was also blind to the study polishing were done of course if needed.
Following the first round of data collection, mucoadhesive pastes preserved in two different containers with different colors. Our pharmacist was aware of the containing. One containing PHT 1% and the other placebo ( Figure 1 ) were applied to randomly selected sextants by a second periodontist who was blind to the study.
Figure 1: Containers in different colors
We also preferred to keep our patients incognizant to prevent any possible bias and/or incompliance, The periodontist in charge of drug application used her index finger to rub this size of paste on the exposed gingival surface so as to cover cervical one third of the teeth. Patients were visited twice daily to receive applications for a week. Earlier, they had their teeth brushed and flossed most meticulously. They also had to abstain from eating and drinking one hour following applications. They were often kept busy in the waiting room so as to make sure they did as instructed.
Any patient who had failed to comply with paste application (7 patients) or refer for follow-up (10 cases) were excluded from the study, out of a total of 37-patients registry.
Preparation of phenytoin mucoadhesive paste
Since buccal phenytoin dosage is not commercially available, the common local skin dosage (1%) was The paste was then inserted into 100 mg contain-composition and preparation method was almost the same except for the fact that it was PHT-free.
We used t-test and paired t-test for comparative
analysis by using SPSS 21 software.
Results
There were statistically significant differences in indices (PPD, BOP and MGI) following three weeks after phenytoin application in test group. There could be seen a decline of 0.93±0.57 mm in PPD on the phenytoin- As can be seen in Table 1 , BOP and MGI were also significantly declining in the phenytoin group. Thus as expected anti-inflammatory effects of PHT were highlighted based on changes in the latter inflammation indices (BOP, MGI). Also it should be noted that in this trial study, any adverse events or side effects were not reported by patients.
Discussion
It has been stated that PHT would accelerate healing rate in surgical wounds following the oral application of the drug. This encouraged the topical applications for skin breaches due to ulcers, burns, skin infections namely impetigo, infected dermatitis and boils, [15] with somewhat mixed results, especially in experimental models. [7] Former research on the role of phenytoin in periodontal lesions healing was disparate in terms of the drug form; such as gel, [12] mouthwash [7, 28] and suspensions. [24] We decided to use mucoadhesive paste 1% considering its longevity in the oral cavity and the relative immunity against potential interventional parameters namely saliva washout and tongue poking.
This also enabled us to suffice to the application of the drug twice per day, which, in turn, made it possible to rule out incompliance as patients, from the walking and driving distances, managed to come and receive medication under our supervision. [23] applied the 1% mucoadhesive paste onto small biopsy-induced lesions, which had healed more quickly as a result. Patients were also reporting a lower incidence of pain. All the above findings were confirmatory of our findings about healing effect and reduce inflammation of topical use of phenytoin. Other studies reported accelerated healing in melanocytic mole removal scars [29] as well as stomatitis-related lesions. [7] Our reports are similar in that pocket lesions are indispensable to periodontitis. Najafi et al. [14] applied the same Topical phenytoin was also shown to have alleviated pain, possibly owing to sodium channel blockage.
[23] Kadkhodazadeh et al. [24] used PHT suspension 1% to soothe pain and induce healing in palatal graft donor sites. PHT was proven superior in these lesions for their being superficial and thus extensive exposure to the solution.
Our study was different, as periodontal pocket wall is less exposed to drug, requiring a longer span of time for healing (3-4 weeks) even under normal circumstances. We also managed to guarantee compliance, in order to diminish confounders. Meanwhile, it would promote pharmacological efficacy, yet more research is warranted to explore the mechanism of action as well as monitoring the healing process in detail.
In a microarray analysis investigating the role of phenytoin in wound healing, Swamy et al. Yet, it still remains unknown as to why PHT fails to stop creeping attachment in gingival graft cases. [14] With the drug inducing some growth factors such as transforming growth factor β (TGF-β) and PDGF, and also up-regulating various matrix remodeling genes and receptors at the messenger RNA (mRNA) level, [11] it sounds that further research is warranted regarding the possible differences between wound/ulcerative lesions and creeping attachment. Our study, however, was limited in certain respects. We were restricted in our choice of patients as we aimed to ensure that compliance was thoroughly fulfilled. We intended to apply the drug ourselves to rule out any possible negligence and/or misapplication.
We did not also investigate the possible mechanism of action as this was beyond the scope of our research. It seems that this has to be further investigated in future studies.
Conclusion
It is shown that the application of PHT mucoadhesive paste following conventional therapy for periodontitis contributes to improve clinical parameters. Given the low cost, relative safety and above all, user-friendly application, the drug seems to be a promising choice of adjunct therapy in cases of chronic periodontitis.
